Management & Regulatory

Are Nigerian Hospitals Ready for Power Outage Emergencies?
Management & Regulatory Are Nigerian Hospitals Ready for Power Outage Emergencies?

In recent years, the healthcare system in Nigeria has faced significant challenges, one of which is the unreliable power infrastructure that plagues many government-run hospitals. This issue is not just an inconvenience but a potential threat to life, as critical medical operations depend on a

States Tackle AI in Healthcare: Balancing Innovation and Safety
Management & Regulatory States Tackle AI in Healthcare: Balancing Innovation and Safety

The rapid integration of artificial intelligence (AI) into healthcare settings across the United States presents significant opportunities and profound challenges. Legislative approaches to regulating AI in healthcare are diverse, reflecting the complex needs of balancing patient safety with

Is ICU Medical Facing Regulatory Challenges Over Infusion Pumps?
Management & Regulatory Is ICU Medical Facing Regulatory Challenges Over Infusion Pumps?

ICU Medical, a prominent medical device company based in California, is currently navigating significant regulatory challenges related to their infusion pumps. These challenges have emerged following an FDA warning, which highlighted the company's failure to adhere to essential regulatory

Evolving Trends and Innovations in Acute Coronary Syndrome Care
Management & Regulatory Evolving Trends and Innovations in Acute Coronary Syndrome Care

The field of acute coronary syndrome (ACS) care has witnessed significant advancements, driven by an evolving understanding of patient management practices and continuous clinical research efforts. These innovations encompass various aspects of treatment, from rethinking established protocols like

Why Are Hedge Funds Investing Big in AI and MedTech Healthcare?
Management & Regulatory Why Are Hedge Funds Investing Big in AI and MedTech Healthcare?

The fourth quarter of 2024 witnessed a significant surge in hedge fund investments focused on the healthcare sector, particularly emphasizing advancements in artificial intelligence (AI), biotechnology, and medical technology (MedTech). This pivotal period showcased growing confidence among

Is Columvi the Game-Changer for Refractory DLBCL Treatment?
Management & Regulatory Is Columvi the Game-Changer for Refractory DLBCL Treatment?

Roche's Columvi, a bispecific antibody known as glofitamab, has been approved by the European Commission (EC) for use in combination with gemcitabine and oxaliplatin (GemOx) to treat relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in adults who are not candidates for autologous stem

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later